Johnson & Johnson
JNJ
Company Profile
Business description
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Contact
One Johnson & Johnson Plaza
New BrunswickNJ08933
USAT: +1 732 524-0400
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
140,800
Johnson & Johnson News & Analysis
markets
US stock market outlook: Where to find value after April’s rally
Our reallocation strategy is working as intended. Opportunities remain in AI, tech, and small-caps.
personal-finance
Howard Marks warns of stock market froth
The renowned investor has penned his first investor letter for 2025 and it’s a ripper. He runs through what bubbles are, which ones he’s experienced, and whether today’s markets qualify as the third major bubble of this century.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.90 | 3.70 | 0.04% |
| CAC 40 | 8,118.60 | 61.17 | -0.75% |
| DAX 40 | 25,401.37 | 167.19 | -0.65% |
| Dow JONES (US) | 52,573.29 | 509.19 | 0.98% |
| FTSE 100 | 10,706.81 | 56.37 | 0.53% |
| HKSE | 24,917.60 | 111.97 | 0.45% |
| NASDAQ | 26,333.04 | 251.31 | 0.96% |
| Nikkei 225 | 63,492.99 | 518.35 | -0.81% |
| NZX 50 Index | 13,560.69 | 19.64 | -0.14% |
| S&P 500 | 7,656.98 | 65.28 | 0.86% |
| S&P/ASX 200 | 8,749.90 | 8.70 | 0.10% |
| SSE Composite Index | 3,885.33 | 2.78 | -0.07% |